Demirsoy Ugur, Sarper Nazan, Aylan Gelen Sema, Zengin Emine, Kum Tugba, Demir Hakan
Departments of *Pediatric Hematology †Biochemistry ‡Nuclear Medicine, Kocaeli University, Kocaeli, Turkey.
J Pediatr Hematol Oncol. 2017 May;39(4):287-292. doi: 10.1097/MPH.0000000000000797.
To investigate the association of calcium (Ca) and vitamin D (vit D) supplementation with bone mineral density (BMD) in pediatric acute lymphoblastic leukemia (ALL).
Group I (n=11): de novo ALL patients aged 1 to 18 years. Group II (n=46): pediatric ALL survivors in first complete remission and ALL patients on maintenance chemotherapy. We stratified group II into 3 subgroups according to the postdiagnosis period (group IIa: 8 to 24 mo, group IIb: 24 to 48 mo, group IIc: >48 mo). Group III (n=22): healthy siblings of group II. Daily oral vit D3 and Ca carbonate was given only to group I. In group I, BMD was measured at diagnosis and after completion of intensive chemotherapy (TP1 and TP2).
A significant increase in Ca (P=0.024) and 25-OH vit D (P=0.01), and a decrease in magnesium (P=0.023) were detected at TP2 compared with TP1 in group I. Mean plasma levels of 25-OH vit D were <20 ng/mL in all the groups. Total body (P=0.005), total body less head (P=0.005), and L1 to L4 BMD Z scores (P=0.025) decreased significantly at TP2 compared with TP1. The lowest BMD scores were found at 8 to 24 months after diagnosis in unsupplemented patients. A gradual increase in BMD Z scores was shown, with the highest scores in group IIc.
Vit D and Ca supplementation in pediatric ALL patients during intensive chemotherapy may not prevent bone mineral loss. BMD scores of pediatric ALL patients described by other studies, as a major decrease in the first 2 years and gradual increase afterward, was also observed in our patients.
探讨补充钙(Ca)和维生素D(vit D)与小儿急性淋巴细胞白血病(ALL)骨密度(BMD)的关系。
第一组(n = 11):1至18岁的初发ALL患者。第二组(n = 46):首次完全缓解的小儿ALL幸存者及维持化疗的ALL患者。根据诊断后时间将第二组分为3个亚组(第二组a:8至24个月,第二组b:24至48个月,第二组c:> 48个月)。第三组(n = 22):第二组患者的健康兄弟姐妹。仅对第一组给予每日口服vit D3和碳酸钙。在第一组中,于诊断时及强化化疗完成后(TP1和TP2)测量骨密度。
与TP1相比,第一组在TP2时钙(P = 0.024)和25 - OH vit D(P = 0.01)显著升高,镁(P = 0.023)降低。所有组的25 - OH vit D平均血浆水平均<20 ng/mL。与TP1相比,TP2时全身(P = 0.005)、全身除头部(P = 0.005)及L1至L4骨密度Z评分(P = 0.025)显著降低。未补充患者在诊断后8至24个月时骨密度评分最低。骨密度Z评分呈逐渐升高趋势,第二组c中评分最高。
小儿ALL患者在强化化疗期间补充vit D和钙可能无法预防骨矿物质丢失。我们的患者也观察到了其他研究中描述的小儿ALL患者骨密度评分在前两年显著下降而后逐渐升高的情况。